氨基观察-创新药组原创出品作者 | 沙晓威谁是度普利尤单抗的潜在挑战者?随着度普利尤单抗加速放量,以及自免领域持续升温,寻找其替代者的呼声也越来越高。在部分中国biotech看来,IL-25或许算一个。作为靶向Th2型炎症反应的细胞因子,理论上它可用于治疗哮喘、特应性皮炎、炎症性肠病等疾病。在该领域,海外药企热度不高,国外大型药企在这一靶点上几乎集体缺席,只有孵化管线的企业Protheragen,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.